QCG
TXG icon

Quadrant Capital Group’s 10x Genomics TXG Stock Holding History

Quadrant Capital Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-982
Closed -$20.8K – 2496
2026
Q1 		$20.8K Hold
982
– – ﹤0.01% 1983
2025
Q4 		$16K Hold
982
– – ﹤0.01% 2071
2025
Q3 		$11.5K Buy
+982
New +$12.8K ﹤0.01% 2125
2025
Q2 		– Sell
-3,900
Closed -$34K – 2542
2025
Q1 		$34K Buy
3,900
+3,748
+2,466% +$47.2K ﹤0.01% 1855
2024
Q4 		$2.18K Sell
152
-102
-40% -$1.61K ﹤0.01% 2485
2024
Q3 		$5.74K Buy
254
+226
+807% +$4.67K ﹤0.01% 2291
2024
Q2 		$545 Sell
28
-67
-71% -$1.75K ﹤0.01% 2612
2024
Q1 		$3.57K Sell
95
-55
-37% -$2.42K ﹤0.01% 2392
2023
Q4 		$8.39K Buy
150
+1
+0.7% +$44 ﹤0.01% 2132
2023
Q3 		$6.15K Hold
149
– – ﹤0.01% 2120
2023
Q2 		$8.32K Hold
149
– – ﹤0.01% 2071
2023
Q1 		$8.31K Sell
149
-82
-35% -$3.83K ﹤0.01% 2101
2022
Q4 		$8.42K Buy
231
+117
+103% +$3.83K ﹤0.01% 2037
2022
Q3 		$3K Buy
114
+66
+138% +$2.51K ﹤0.01% 2302
2022
Q2 		$2K Sell
48
-51
-52% -$2.65K ﹤0.01% 2284
2022
Q1 		$8K Buy
99
+1
+1% +$87 ﹤0.01% 1760
2021
Q4 		$15K Buy
98
+36
+58% +$5.51K ﹤0.01% 1454
2021
Q3 		$9K Buy
62
+4
+7% +$687 ﹤0.01% 1662
2021
Q2 		$11K Sell
58
-43
-43% -$7.78K ﹤0.01% 1524
2021
Q1 		$18K Buy
101
+50
+98% +$8.63K ﹤0.01% 1238
2020
Q4 		$7K Buy
+51
New +$7.4K ﹤0.01% 1595
2020
Q3 		– Sell
-151
Closed -$13K – 2311
2020
Q2 		$13K Buy
+151
New +$11.8K ﹤0.01% 1228

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrant Capital Group's TXG Position: Q2 2026 in Review

Quadrant Capital Group sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 982 shares — an estimated $20.8K sold.

Quadrant Capital Group first reported a position in TXG in Q2 2020 and held it in 22 quarters. The position peaked at $34K in Q1 2025. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Quadrant Capital Group reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 982 10x Genomics shares in Q2 2026, an estimated $20.8K.
  • Quadrant Capital Group first reported a position in 10x Genomics in Q2 2020 and held it in 22 quarters.
  • Quadrant Capital Group's 10x Genomics position peaked at $34K in Q1 2025.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.